Podcast: TRK fusion-positive lung cancer
Podcast: TRK fusion-positive lung cancer
Prof. Christian Rolfo, Assoc. Prof. Caterina Marchiò
In this NTRK CONNECT podcast Assoc. Prof. Caterina Marchiò and Prof. Christian Rolfo discuss the detection and management of TRK fusion-positive lung cancer.Prof. Christian Rolfo
Medical Oncologist
Mount Sinai Hospital
United States (US)
Prof. Christian Rolfo has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Assoc. Prof. Caterina Marchiò
Pathologist
University of Turin
Italy
Assoc. Prof. Caterina Marchiò has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Podcast | 20 min | Jan 2022
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
download resources
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
In this podcast, NTRK CONNECT members Assoc. Prof. Caterina Marchiò (University of Turin, Italy) and Prof. Christian Rolfo (Center of Thoracic Oncology Tisch Cancer Institute Icahn School of Medicine at Mount Sinai, New York, USA) provide pathologist and medical oncologist perspectives about the detection and treatment of TRK fusion-positive lung cancer.
They discuss a number of techniques and strategies to identify this rare fusion in lung cancer patients, before going on to summarise the robust efficacy and safety data for both entrectinib and larotrectinib. Prof. Rolfo briefly covers second-generation therapies in clinical development and describes how liquid biopsy is emerging as a new technique to identify and monitor patients. They conclude by stressing the importance of the collaboration and communication between pathologists and oncologists to test for and identify TRK fusion-positive lung cancer patients.
Podcast Transcript
Caterina Marchió
Welcome everybody, today we are here for this podcast that is going to be covering lung cancer and the detection of NTRK gene fusion in lung cancer. I'm welcoming you here on behalf of the NTRK CONNECT group and the podcast will be dealt by a pathologist, I'm the pathologist, and I will be here with a medical oncologist. I'm Caterina Marchiò and I'm a molecular pathologist working at the University of Turin. I work at a cancer Institute, at The Candiolo Cancer Institute in Turin. Today I'm here with Christian Rolfo my co-chair medical oncologist.
Christian Rolfo
Hi Caterina, good afternoon and so I'm Christian Rolfo, I'm a thoracic oncologist at the Center of Thoracic Oncology at Mount Sinai in New York, Icahn School of Medicine and it's a pleasure to discuss today this important topic in lung cancer....
This NTRK CONNECT podcast is also available on Castos, Spotify, Apple Podcasts and Google Podcasts.
This programme is supported by an Independent Educational Grant from Bayer
PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer.